Formulation and In-Vitro Evaluation of Piroxicam Loaded BSA Nanospheres by Desolvation

Sravya Neela Kiran Babu

doi:10.4172/2157-7439.1000289

Abstract

Protein nanoparticles offer improved delivery of drugs particularly targeted delivery to specific cells by ligand attachment, sustained and triggered release. Non steroidal anti-inflammatory drug (NSAID), Piroxicam (PRX) is one of the most widely used drug for treating pain and inflammation. But despite its potent analgesic action it has few draw backs like low absorption rate due to poor water solubility and side effects due to non specific inhibition of Cyclooxygenase enzymes. In this context here, we report a new PRX self-assembled nano sphere delivery system developed from bovine serum albumin (BSA) using a very simple, rapid and reliable method, desolvation. Synthesized nanoparticles were characterized by particle size distribution, zeta potential, polydispersity index, FTIR, scanning electron microscopy and in-vitro release studies. The formulated BSA-PRX nano particles exhibited a uniform spherical shape with an average size of 388.7nm. In vitro release behavior of the drug from BSA conjugate suggests that about 50% of the drug was released during first 3h and 85% after 18h.

Highlights

Piroxicam (PRX) is a non-steroidal anti-inflammatory drug that is most widely used in the treatment of rheumatic conditions like inflammation, pain due to injury, menstrual cramps, arthritis, and other musculoskeletal conditions and non-rheumatic conditions like biliary and ureteric colic, dysmenorrheal inflammation and fever [1]
COX-1 is involved in maintaining the physiological function of the gastrointestinal and renal tracts where as COX-2 participates in the pain and inflammation [3]
Piroxicam (PRX), fatty acid free bovine serum albumin (BSA), ethanol and glutaraldehyde were purchased from Sigma Aldrich, India

Summary

Introduction

Piroxicam (PRX) is a non-steroidal anti-inflammatory drug that is most widely used in the treatment of rheumatic conditions like inflammation, pain due to injury, menstrual cramps, arthritis, and other musculoskeletal conditions and non-rheumatic conditions like biliary and ureteric colic, dysmenorrheal inflammation and fever [1]. PG mediates many physiological functions of the body, including control of blood pressure; control of respiratory and gastrointestinal tract smooth muscles [2]. COX-1 is involved in maintaining the physiological function of the gastrointestinal and renal tracts where as COX-2 participates in the pain and inflammation [3]. Anti-inflammatory actions of PRX are due to the inhibition of COX-2 only whereas the inhibition of COX-1 leads to the unwanted side-effects like dyspepsia, heartburn, nausea and vomiting [4]. There is a considerable interest in developing new formulations of PRX to improve its oral absorption rate as well as to target COX-1specific [5]

Objectives

Methods

Results

Conclusion